fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Cefixime

Form:

4 of 4 products shown

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.

Auro-Cefixime · DIN 02468689 · 20 mg/mL · Oral suspension

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
1 brand, same coverage
Auro-Cefixime · DIN 02468689 Manufacturer: Auro Pharma Inc.; listing date 2019-11-29 Health Canada: Marketed since 2018-01-08 · brand AURO-CEFIXIME · ATC J01DD08 CEFIXIME · form Powder for suspension · route Oral · ingredients CEFIXIME 100 MG/5ML · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Auro-Cefixime: Formulary list price $0.39 per unit (the source does not state the unit; exact figure $0.3899). What the ministry pays, not the patient.

Ministry pays: $0.3899 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02468689)

Source record
DIN 02468689: Auro-Cefixime Raw flags: sec3=Y Item: 081228054; group id 38; item number 0077; lccId None; manufacturer id AUR Source form: Oral Susp; strength: 20mg/mL Recorded listing: General benefit Source prices (unrounded): $0.3899; ministry $0.3899 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02468689 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95716
Interchangeable products
Suprax · DIN 00868965 · $0.3899
Shortage status: active shortage (reported January 29, 2026, estimated to end September 30, 2026, last updated August 31, 2026); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02468689
Shortage record checked October 6, 2026

Suprax · DIN 00868965 · 20 mg/mL · Oral suspension

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
1 brand, same coverage
Suprax · DIN 00868965 Manufacturer: Odan Laboratories Ltd.; listing date 1996-10-01 Health Canada: Marketed since 2017-07-14 · brand SUPRAX · ATC J01DD08 CEFIXIME · form Powder for suspension · route Oral · ingredients CEFIXIME 100 MG/5ML · company Odan laboratoriesltd · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Suprax: Formulary list price $0.39 per unit (the source does not state the unit; exact figure $0.3899). What the ministry pays, not the patient.

Ministry pays: $0.3899 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00868965)

Source record
DIN 00868965: Suprax Raw flags: sec3=Y Item: 081228054; group id 38; item number 0077; lccId None; manufacturer id ODN Source form: Oral Susp; strength: 20mg/mL Recorded listing: General benefit Source prices (unrounded): $0.3899; ministry $0.3899 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00868965 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10523
Interchangeable products
Auro-Cefixime · DIN 02468689 · $0.3899
Shortage status: resolved shortage (ended January 25, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00868965
Shortage record checked October 6, 2026

Auro-Cefixime · DIN 02432773 · 400 mg · tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
1 brand, same coverage
Auro-Cefixime · DIN 02432773 Manufacturer: Auro Pharma Inc.; listing date 2014-12-18 Daily cost (source): $2.7172 Health Canada: Marketed since 2014-10-24 · brand AURO-CEFIXIME · ATC J01DD08 CEFIXIME · form Tablet · route Oral · ingredients CEFIXIME 400 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Auro-Cefixime: Formulary list price $2.72 per unit (the source does not state the unit; exact figure $2.7172). What the ministry pays, not the patient.

Ministry pays: $2.7172 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02432773)

Source record
DIN 02432773: Auro-Cefixime Raw flags: sec3=Y Item: 081228056; group id 38; item number 0078; lccId None; manufacturer id AUR Source form: Tab; strength: 400mg Recorded listing: General benefit Source prices (unrounded): $2.7172; ministry $2.7172 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02432773 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91720
Interchangeable products
Suprax · DIN 00868981 · $2.7172
Shortage status: resolved shortage (ended November 15, 2024); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02432773
Shortage record checked October 6, 2026

Suprax · DIN 00868981 · 400 mg · tablet

General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
1 brand, same coverage
Suprax · DIN 00868981 Manufacturer: Odan Laboratories Ltd.; listing date 1996-10-01 Daily cost (source): $2.7172 Health Canada: Marketed since 2017-07-14 · brand SUPRAX · ATC J01DD08 CEFIXIME · form Tablet · route Oral · ingredients CEFIXIME 400 MG · company Odan laboratoriesltd · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Suprax: Formulary list price $2.72 per unit (the source does not state the unit; exact figure $2.7172). What the ministry pays, not the patient.

Ministry pays: $2.7172 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00868981)

Source record
DIN 00868981: Suprax Raw flags: sec3=Y Item: 081228056; group id 38; item number 0078; lccId None; manufacturer id ODN Source form: Tab; strength: 400mg Recorded listing: General benefit Source prices (unrounded): $2.7172; ministry $2.7172 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00868981 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10525
Interchangeable products
Auro-Cefixime · DIN 02432773 · $2.7172
Shortage status: resolved shortage (ended November 30, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00868981
Shortage record checked October 6, 2026

Other products in the same Health Canada class (J01D, J01DD): coverage varies; not interchangeable

  • Ceftriaxone (Rocephin): general benefit, not a benefit
  • Cefadroxil (Duricef): general benefit, not a benefit
  • Cefprozil (Ran-Cefprozil): general benefit, not a benefit
  • Cefuroxime axetil (Ceftin): general benefit, not a benefit
  • Cephalexin (Ceporex): general benefit, not a benefit
  • Cefazolin (Cefazolin for Injection): not a benefit

1 more in the class list below

Other drugs in the same formulary class (08:12:28 Other Antibiotics) and how they are covered

Matched class: 08:12:28 Other Antibiotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CLINDAMYCIN PALMITATE Some products covered without a code (check the product listing): CEFADROXIL, CEFPROZIL, CEFTRIAXONE DISODIUM, CEFUROXIME AXETIL, CEPHALEXIN MONOHYDRATE, CLINDAMYCIN HCL, TOBRAMYCIN, TOBRAMYCIN SULFATE 08:12:28 Other Antibiotics

CEFTRIAXONE DISODIUM

· 16 products · Listed, not a benefit (3), General benefit (9), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 0.25g/Vial, 1g/Vial, 2g/Vial, 10g/Vial · Inj Pd-Vial Pk

CEFADROXIL

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: 500mg · Cap

CEFPROZIL

· 17 products · General benefit (11), Listed, not a benefit (6) · strengths: 125mg/5mL, 250mg/5mL, 250mg, 500mg · Oral Susp-100mL Pk, Oral Susp-75mL Pk, Tab

CEFUROXIME AXETIL

· 9 products · General benefit (7), Listed, not a benefit (2) · strengths: 125mg/5mL, 250mg, 500mg · Susp, Tab

CEPHALEXIN MONOHYDRATE

· 29 products · Listed, not a benefit (6), General benefit (23) · strengths: 250mg, 500mg, 25mg/mL, 50mg/mL · Cap, Pd for Oral Susp, Tab

CEFAZOLIN SODIUM

· 15 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 500mg/Vial, 1g/Vial, 10g/Vial · Inj Pd-Vial Pk, Inj Pd-Vial Pk (Preservative-Free)

CEFOXITIN SODIUM

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1g/Vial, 2g/Vial · Inj Pd-Vial Pk

CLINDAMYCIN HCL

· 22 products · Listed, not a benefit (2), General benefit (20) · strengths: 150mg, 300mg · Cap

CLINDAMYCIN PALMITATE

· 1 products · General benefit · strengths: 15mg/mL · Pd for Oral Susp

TOBRAMYCIN

· 3 products · Limited Use, codes 472 (1), General benefit (2) · strengths: 28mg, 300mg/5mL · Inh Pd-Cap, Inh Sol-5mL Pk

TOBRAMYCIN SULFATE

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: 80mg/2mL · Inj Sol-2mL Pk

DALBAVANCIN HYDROCHLORIDE

· 1 products · Limited Use, codes 677 · strengths: 500mg/Vial · Pd for Sol (Preservative-Free) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 08:12:28 and 4 more
Full class listing Related classes: 08:12:04 Antifungals, 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:16 Penicillins, 08:12:24 Tetracyclines, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND USAGE SUPRAX (cefixime) is indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms: Upper Respiratory Tract: Pharyngitis and tonsillitis caused by S. pyogenes. Middle Ear: Otitis media caused by S. pneumoniae, H. influenzae (beta-lactamase positive and negative strains), M. catarrhalis (former B. catarrhalis) (beta-lactamase positive and negative strains) and S. pyogenes. Paranasal sinuses: Sinusitis caused by S. pneumoniae, H. influenzae (beta-lactamase positive and negative strains), and M. catarrhalis (former B. catarrhalis) (beta-lactamase positive and negative strains). Lower Respiratory Tract: Acute bronchitis caused by S. pneumoniae, M. catarrhalis (former B. catarrhalis) (beta-lactamase positive and negative strains) and H. influenzae (beta-lactamase positive and negative strains). Page 2 of 30 Urinary Tract: Acute uncomplicated cystitis and urethritis caused by E. coli, P. mirabilis, and Klebsiella species. Uncomplicated Gonorrhea: Uncomplicated gonorrhea (cervical/ur… https://pdf.hres.ca/dpd_pm/00056119.PDF PM date: March 17, 2020 Source product: SUPRAX; DIN 00868965; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Auro-Cefixime · DIN 02468689 Shortage status: active shortage (reported 2026-01-29, estimated to end 2026-09-30, last updated 2026-08-31); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02468689

Check this DIN again